ClinicalTrials.gov
public full text
Public Domain
Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 42 U.S.C. § 300cc-18 — Development of model protocols for clinical care of infected individuals#594677
- Drug Repurposing for Rare Diseases#976506
- A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris#911828
- A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants#908189
- Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)#916542
Record · ID 1126770
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive